- In January 2025, Hologic announced the commercial launch of its Affirm Prone Biopsy System in North America. This system enhances the precision of breast biopsies by providing more accurate tissue samples while increasing patient comfort. The system is designed for use with 3D mammography, offering superior imaging and guiding precision during biopsy procedures
- In October 2024, GE Healthcare unveiled its Pristina Dueta, an innovative breast biopsy device that incorporates a unique, patient-controlled compression feature. This breakthrough design allows patients to adjust the compression level during the biopsy, which minimizes discomfort while enhancing the overall accuracy of the biopsy process. The system is designed for use with advanced imaging technologies and is aimed at improving the overall experience and diagnostic outcomes
- In September 2024, Siemens Healthineers announced the launch of its Mammomat Revelation with Biopsy Option in Europe. This system combines digital breast tomosynthesis with an advanced biopsy attachment, enabling precise targeting of abnormalities with minimal discomfort. The device aims to improve early breast cancer detection and biopsy accuracy, focusing on patient-centric care
- In December 2024, Cook Medical introduced a new line of biopsy needles, designed for both fine-needle aspiration (FNA) and core needle biopsies, equipped with a novel safety feature to reduce risk during the procedure. These devices are expected to provide greater precision and safety, benefiting both patients and healthcare professionals by minimizing complications and improving overall biopsy outcomes
- In March 2021, IZI Medical Products, LLC ("IZI") launched The Quick-Core Auto Biopsy System for the purpose of soft tissue biopsy. Quick-Core Auto is known to be a lightweight, completely automatic biopsy equipment offering precision, reliability, and quality of IZI's Quick-Core semi-automatic biopsy system
